0.59 USD
▲+0.01+3.02%
2026-08-03
市值
$4.50M
市盈率
—
EPS
-0.46
股息率
—
52 周区间
0.53 – 1.88
成交量
27.46K
Beta
2.05
目标价
—
52W 低 0.5352W 高 1.88
价格走势
公司简介
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an ...